Event driven look at Charles River Laboratories International Charles River Laboratories International (CRL) is back in focus after launching rapid cell banking programs that aim to cut cell bank production timelines by 40% compared with the typical 20 week industry standard. Recent trading has been choppy. The share price is down 7.12% over the past month but up 30.38% over 90 days and 37.01% year to date, while the 1 year total shareholder return of 85.57% signals strong longer term...

Charles River Laboratories (CRL) stock rises as the company targets the high end of 2026 guidance and unveils 2030 outlook. Read more here.

Event driven look at Charles River Laboratories International Charles River Laboratories International (CRL) is back in focus after launching rapid cell banking programs that aim to cut cell bank production timelines by 40% compared with the typical 20 week industry standard. Recent trading has been choppy. The share price is down 7.12% over the past month but up 30.38% over 90 days and 37.01% year to date, while the 1 year total shareholder return of 85.57% signals strong longer term...

Reitera el crecimiento orgánico de los ingresos del año fiscal 26 en el extremo superior del 0-1%. Establece el objetivo de CAGR de ingresos orgánicos para 2027-2030 en 5-7%. Apunta a un margen operativo no GAAP de ~24% para 2030, frente al 21,0-21,3% en el año fiscal 26. Guía las EPS no GAAP del año fiscal 26 al extremo superior de $11,15-$11,45.

Las acciones de Charles River Laboratories se situaron en 277,33 dólares el 23 de septiembre de 2026, mientras que los ingresos del segundo trimestre alcanzaron

WILMINGTON, Mass., 24 de septiembre de 2026--Charles River destaca su visión estratégica renovada para impulsar el crecimiento rentable y la creación de valor a largo plazo en el Día del Inversor de 2026

Charles River Laboratories stock stood at USD 277.33 on September 23, 2026, 8.56 percent below its 5

WILMINGTON, Mass., 24 de septiembre de 2026--Charles River destaca su visión estratégica renovada para impulsar el crecimiento rentable y la creación de valor a largo plazo en el Día del Inversor de 2026

Charles River Laboratories International has seen its share price move sharply over the past year, and that kind of run naturally raises a question for you as an investor. Are the cash flows that the business can generate enough to support where the stock now trades? The stock has returned 102.3% over the past 12 months, which puts real pressure on the case that its current valuation can still be explained by its underlying cash generation. Recent moves to expand outsourced services in areas...

Las acciones de la empresa de servicios de laboratorio Charles River Laboratories (NYSE:CRL) subieron un 5,7 % en la sesión de la tarde después de que la compañía describiera sus objetivos financieros a largo plazo hasta 2030 y elevara sus perspectivas de ganancias para 2026 en su Día del Inversor.